BRD1652
BRD1652 is a highly selective and potent GSK3 inhibitor. BRD1652 demonstrates in vivo efficacy in a dopaminergic signaling paradigm modeling mood-related disorders. The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3).
| Supplier | Ace Therapeutics |
|---|---|
| Product # | SMD557 |
| CAS # | 1597438-92-0 |
| Pricing | Customizable size, Inquiry |
| Synonym | BRD1652; BRD-1652; BRD 1652; |
| Product Category | Lab-use Small Molecule Drugs |
| Chemical Formula | C20H20F3N3O |
| Exact Mass | 375.1558 |
| Molecular Weight | 375.4 |
| Elemental Analysis | C, 63.99; H, 5.37; F, 15.18; N, 11.19; O, 4.26 |
| IUPAC/Chemical Name | (S)-4,7,7-Trimethyl-4-phenyl-3-trifluoromethyl-2,4,6,7,8,9-hexahydro-pyrazolo[3,4-b]quinolin-5-one |
| InChi Key | HSFYCTPGOPYGHQ-LJQANCHMSA-N |
| InChi Code | InChI=1S/C20H20F3N3O/c1-18(2)9-12-14(13(27)10-18)19(3,11-7-5-4-6-8-11)15-16(20(21,22)23)25-26-17(15)24-12/h4-8H,9-10H2,1-3H3,(H2,24,25,26)/t19-/m1/s1 |
| SMILES Code | O=C1C2=C(NC3=NNC(C(F)(F)F)=C3[C@]2(C)C4=CC=CC=C4)CC(C)(C)C1 |
| Appearance | Solid powder |
| Purity | >98% (or refer to the Certificate of Analysis) |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Shelf Life | >2 years if stored properly |
| Drug Formulation | This drug may be formulated in DMSO |
| Stock Solution Storage | 0 - 4℃ for short term (days to weeks), or -20℃ for long term (months). |
| HS Tariff Code | 2934.99.9001 |